Interrupted time-series analyses of routine vaccination program for elderly pneumonia patients in Japan; an ecological study using aggregated nationwide inpatient data.

Koichi Kobayashi, Taisuke Jo, Wataru Mimura, Maho Suzukawa, Nobuharu Ohshima, Goh Tanaka, Manabu Akazawa, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga, Takahide Nagase, Hideaki Nagai
Author Information
  1. Koichi Kobayashi: Department of Internal medicine, Yoshikawa Central General Hospital, Saitama, Japan. ORCID
  2. Taisuke Jo: Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  3. Wataru Mimura: Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan. ORCID
  4. Maho Suzukawa: Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.
  5. Nobuharu Ohshima: Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan. ORCID
  6. Goh Tanaka: Department of Respiratory Medicine, The University of Tokyo, Tokyo, Japan.
  7. Manabu Akazawa: Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan.
  8. Hiroki Matsui: Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
  9. Kiyohide Fushimi: Department of Health Policy and Informatics, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
  10. Hideo Yasunaga: Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
  11. Takahide Nagase: Department of Respiratory Medicine, The University of Tokyo, Tokyo, Japan.
  12. Hideaki Nagai: Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.

Abstract

A national routine pneumococcal pneumonia immunization program started in Japan in 2014. It targeted the population aged ≥65 years and used a 23-valent pneumococcal polysaccharide vaccine; PPSV23. However, its effectiveness was not well defined because of the lack of a comprehensive database on the PPSV23 vaccination status of each subject. We used interrupted time-series analyses to assess the changes in the incidence and prognosis of elderly patients hospitalized for pneumonia before and after initiation of the program. First, we estimated the PPSV23 coverage rates in subjects aged ≥65 years based on the number of shipped PPSV23 syringes and the estimated population in each prefecture. The estimated coverage rates reached around 40% in 2014 for the 3 Tohoku prefectures, while those in the other prefectures remained below 20%. After the national routine immunization program started, the estimated coverage rate increased significantly in every prefecture and exceeded 40% in 2017. Next, we aggregated the data extracted from the Japanese Diagnosis Procedure Combination database from April 2011 through February 2017 for hospitalized pneumonia patients aged ≥65 years. The data included data from 655,746 patients, excluding those in the 3 Tohoku prefectures. Interrupted time-series analyses found no change in the incidence of hospitalized pneumonia patients and in-hospital mortality after the vaccination program, but there was a decrease in the in-hospital mortality of pneumonia patients with severe comorbidities defined by the modified Charlson comorbidity index. These results suggest an association between the vaccination program and an improved outcome in hospitalized elderly pneumonia patients with severe comorbidities in Japan.

Keywords

References

  1. PLoS One. 2015 Mar 30;10(3):e0122247 [PMID: 25822890]
  2. Int J Epidemiol. 2017 Feb 1;46(1):348-355 [PMID: 27283160]
  3. Vaccine. 2017 May 19;35(22):2882-2891 [PMID: 28449971]
  4. Sci Rep. 2015 Oct 21;5:15314 [PMID: 26486591]
  5. J Epidemiol. 2017 Oct;27(10):476-482 [PMID: 28142051]
  6. N Engl J Med. 2003 May 1;348(18):1747-55 [PMID: 12724480]
  7. Vaccine. 2010 Oct 8;28(43):7063-9 [PMID: 20723631]
  8. Jpn Clin Med. 2018 Jan 03;9:1179670717751433 [PMID: 29434484]
  9. Vaccine. 2015 Nov 9;33(45):6054-60 [PMID: 26235372]
  10. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD000422 [PMID: 23440780]
  11. N Engl J Med. 1991 Nov 21;325(21):1453-60 [PMID: 1944423]
  12. Vaccine. 2019 Aug 14;37(35):4853-4857 [PMID: 31327653]
  13. Lancet. 2007 Apr 7;369(9568):1179-86 [PMID: 17416262]
  14. Sci Transl Med. 2013 Jun 26;5(191):191ra84 [PMID: 23803706]
  15. Intern Med. 2013;52(3):317-24 [PMID: 23370738]
  16. BMJ. 2010 Mar 08;340:c1004 [PMID: 20211953]
  17. Emerg Infect Dis. 2018 Nov;24(11):2010-2020 [PMID: 30334707]
  18. PLoS Med. 2013;10(9):e1001517 [PMID: 24086113]
  19. Vaccine. 2016 Mar 18;34(13):1496-1503 [PMID: 26899376]
  20. Emerg Infect Dis. 2015 Nov;21(11):1956-65 [PMID: 26485679]
  21. Vaccine. 2009 Aug 6;27(36):4891-904 [PMID: 19520205]
  22. JAMA. 2005 Dec 7;294(21):2712-9 [PMID: 16333006]
  23. Pneumonia (Nathan). 2017 Dec 5;9:19 [PMID: 29226070]
  24. Lancet Infect Dis. 2017 Mar;17(3):313-321 [PMID: 28126327]
  25. J Infect. 2012 Sep;65(3):223-30 [PMID: 22543245]
  26. F1000Res. 2018 Feb 1;7:135 [PMID: 29744035]
  27. PeerJ. 2018 Dec 12;6:e6085 [PMID: 30581675]
  28. mBio. 2011 Jan 25;2(1):e00309-10 [PMID: 21264063]
  29. BMC Infect Dis. 2017 Jan 3;17(1):2 [PMID: 28049447]
  30. CMAJ. 2009 Jan 6;180(1):48-58 [PMID: 19124790]
  31. Pulmonology. 2018 Feb 17;: [PMID: 29463455]
  32. Clin Infect Dis. 2006 Apr 15;42(8):1093-101 [PMID: 16575726]
  33. Vaccine. 2017 Oct 13;35(43):5776-5785 [PMID: 28911902]
  34. MMWR Morb Mortal Wkly Rep. 2009 Oct 2;58(38):1071-4 [PMID: 19798021]
  35. Respir Med. 2008 Sep;102(9):1287-95 [PMID: 18602805]
  36. Respirology. 2006 Jul;11(4):429-36 [PMID: 16771912]

MeSH Term

Aged
Humans
Immunization Programs
Inpatients
Japan
Pneumococcal Infections
Pneumococcal Vaccines
Pneumonia, Pneumococcal
Vaccination

Chemicals

Pneumococcal Vaccines

Word Cloud

Created with Highcharts 10.0.0pneumoniapatientsprogrampneumococcalPPSV23vaccinationhospitalizedestimateddataroutineJapanageddatabasetime-seriesanalyseselderlycoverageprefecturesnationalimmunizationstarted2014population≥65 yearsusedpolysaccharidevaccinedefinedincidenceratesprefecture40%3Tohoku2017aggregatedJapaneseInterruptedin-hospitalmortalityseverecomorbiditiesinpatienttargeted23-valentHowevereffectivenesswelllackcomprehensivestatussubjectinterruptedassesschangesprognosisinitiationFirstsubjects≥65 yearsbasednumbershippedsyringesreachedaroundremained20%rateincreasedsignificantlyeveryexceededNextextractedDiagnosisProcedureCombinationApril2011Februaryincluded655746excludingfoundchangedecreasemodifiedCharlsoncomorbidityindexresultssuggestassociationimprovedoutcomeecologicalstudyusingnationwideElderlydiagnosisprocedurecombination

Similar Articles

Cited By